Published on 23 May 2023 on Zacks via Yahoo Finance
Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag
Bayer Aktiengesellschaft BAYRY announced that the FDA has granted Fast Track Designation (FTD) to its investigational drug, asundexian, as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF).
We would like to remind the investors that asundexian was first granted FTD in 2022 for the prevention of stroke in patients after a non-cardioembolic ischemic stroke.
In the past year, shares of Bayer have plunged 11.4% against the industry’s 12.2% rise.